Table 3.
Selected studies of alloHCT in T-PLL
| Publication | Study | No. patients | Remission status at alloHCT (N) | Donor type | Regimen intensity (N) | Outcomes |
|---|---|---|---|---|---|---|
| Wiktor-Jedrzejczak et al. 13 | EBMT | 37 a | CR=22 PR=10 Other=5 |
MRD=15 MUD=22 |
MAC=13 RIC=24 |
4 year OS: 42% 4 year NRM: 32% 4 year relapse: 38% |
| Kalaycio et al.10 | CIBMTR | 47 (21 T-PLL)b | CR=16 PR=8 Other=21 |
MRD=11 MUD=19 Other: 13 |
MAC=19 NMA=14 |
1 year OS: 48% 1 year NRM: 28% 1 year relapse: 28% |
| Guillaume et al. 9 | SFGM-TC | 27 | CR=14 PR=10 Other=3 |
MRD=10 MUD=17 |
MAC=10 NMA=17 |
3 year OS: 36% 3 year NRM: 31% 3 year relapse: 47% |
| Dholaria et al. 8 | Moffitt Cancer Center |
11 | CR=9 PR=1 Other=1 |
MRD =5 MUD=3 Other=3 |
MAC=8 RIC=3 |
4 year OS: 56% 4 year NRM: 34% 4 year relapse: 21% |
| Yamasaki et al. 14 | JSHCT | 20 | CR=6 PR=1 Other=13 |
MRD =5 MUD=6 Haplo=2 MMUD=7 UCB: 2 |
MAC=10 RIC=10 |
3 year OS: 39.8% 1 year NRM: 20.9% 3 year relapse: 69.6% |
| Murthy et al (current study) | CIBMTR | 266 | CR=149 PR= 80 Other=37 |
MRD =80 MUD=115 Haplo=30 MMUD=33 Other=8 |
MAC=78 RIC=188 |
4 year OS: 30% 4 year TRM: 32.4% 4 year relapse: 41.9% |
Abbreviations: B-PLL, B cell prolymphocytic leukemia; CIBMTR, Center for International Blood and Marrow Transplant Research; CR, complete remission; EBMT, European Society for Blood and Marrow Transplantation; haplo, haploidentical donor; HCT, hematopoietic cell transplantation; JSHCT, Japan Society for Hematopoietic Cell Transplantation (now known as the Japanese Society for Transplantation and Cellular Therapy; MRD, matched related donor; MMUD, mismatched unrelated donor; MUD, matched unrelated donor; NRM, nonrelapse mortality; OS, overall survival; PR, partial response; SFGM-TC, Francophone Society of Bone Marrow Transplantation and Cellular Therapy; T-PLL, T-cell prolymphocytic leukemia; UCB, umbilical cord blood.
Data available for 36 patients
B-PLL and T-PLL